Comparative Pharmacology
Head-to-head clinical analysis: GONAL F RFF REDI JECT versus REPRONEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GONAL F RFF REDI JECT versus REPRONEX.
GONAL-F RFF REDI-JECT vs REPRONEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian follicles, stimulating follicular growth, maturation, and estrogen production.
REPRONEX (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth in women who do not have primary ovarian failure. It acts by binding to FSH receptors on granulosa cells, increasing cAMP and promoting follicular development and estrogen synthesis.
Subcutaneous injection. Initial dose 75-225 IU once daily for 7-14 days, titrated based on ovarian response. Maximum daily dose 450 IU.
Men: 1000-2500 IU subcutaneously 3 times weekly for 6-12 months. Women: 75-300 IU subcutaneously or intramuscularly daily for 7-12 days.
None Documented
None Documented
Terminal elimination half-life: approximately 24 hours; clinically, steady-state is achieved within 3-5 days of daily dosing.
Terminal elimination half-life: 24-30 hours (menotropins); clinically, it supports daily dosing during ovarian stimulation
Renal: approximately 70-80% of the dose; fecal: <20%
Renal (approximately 80% as parent drug and metabolites); biliary/fecal (<5%)
Category C
Category C
Gonadotropin
Gonadotropin